Explore how a new cardio kidney screening workflow boosts urine testing efficiency, narrowing gaps in metabolic health and improving patient outcomes at…
Medicare’s 2.5% dermatology reimbursement increase for 2026 falls short, leaving clinics struggling with rising costs and denied user access.
The FTC settlement with Caremark and Zinc Health targets pharmacy benefit managers to lower insulin costs and improve transparency for consumers.
The U.S. Medicare drug pricing policy may cut costs by matching prices in other wealthy nations, reshaping pharmaceutical research priorities.
A new COVID-19 antibody treatment, VYD2311, enters phase 3 trials to evaluate safety and efficacy against mRNA vaccines.